XM does not provide services to residents of the United States of America.
Z
Z

Zimmer

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Zimmer Biomet Announces CE Mark Certification

BRIEF-Zimmer Biomet Announces CE Mark Certification Nov 18 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET ANNOUNCES CE MARK CERTIFICATION FOR PERSONA® REVISION KNEE SYSTEM Source text: ID:nPn8Qy96La Further company coverage: ZBH.N
Z

U.S. STOCKS Zimmer Biomet, Shake Shack, Microsoft

BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes advanced on Wednesday, with the tech-heavy Nasdaq rising to a record high, as investors assessed corporate earnings as well as crucial data showing the economy maintained a steady pace of growth in the third quarter.
A
A
B
C
C
D
E
G
M
M
N
Q
Q
V
A
K
S
U
U
G
W
Z
D
F
O

Zimmer Biomet rises on lower-than-expected 2024 profit forecast cut

BUZZ-Zimmer Biomet rises on lower-than-expected 2024 profit forecast cut ** Shares of Zimmer Biomet ZBH.N rise 4.2% to $108.20 in morning trade ** Stock set for its best day in over a year if gains hold ** Medical device maker now expects 2024 adj EPS between $7.95 and $8.05, down from its prior forecast range of $8.00 to $8.15 ** EPS forecast cut
Z

Zimmer Biomet Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary

Zimmer Biomet Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary Zimmer Biomet Holdings Inc ZBH.N reported quarterly adjusted earnings of $1.74​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.65. The mean expectation of twenty eight analysts for the quarter was for earnings of $1.74 per share.
Z

Implant maker Zimmer Biomet lowers full-year profit forecast

Implant maker Zimmer Biomet lowers full-year profit forecast Oct 30 (Reuters) - Hip implant maker Zimmer Biomet ZBH.N lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations. Zimmer Biomet said in September it had to replace its enterprise resource planning (ERP) system due to "usual glitches".
S
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.